Drug Trial Radar · NCT06536491
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Aug 19, 2024
Primary completion
Oct 15, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Eclipse Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).
Conditions
- Diabetic Macular Edema
Interventions
EC-104 high doseDrug
Intravitreal injection
EC-104 low doseDrug
Intravitreal injection
Dexamethasone intravitreal implantDrug
Marketed product intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular and Systemic SafetyTime frame: Through Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Retina Associates of Florida, LLC
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.